Evidence mapPaperPMID 9732337Full record

Trial reportBMJ (Clinical research ed.)1998

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Erratum issued 4 registry-linked trialsAbstract readClinical TrialComparative StudyMulticenter Study
In one paragraph

Trial report in BMJ (Clinical research ed.), 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 1,814 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,814citing papers in PubMed, 23 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02879409 naactive not recruitingstarted 2016, after this paper: background citation

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Ran2016Enrolled150Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2Armsdapagliflozin, Gliclazide, human insulin, liraglutide, Metformin
Open the trial in the graph
NCT00328601 phase3completednot on this mapstarted 2005, after this paper: background citation

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups

TypeinterventionalSponsorMEDA Pharma GmbH & Co. KGRan2005 to 2005Enrolled170ConditionsDiabetic PolyneuropathyArmsThioctic Acid
NCT02974816 nacompletednot on this mapstarted 2017, after this paper: background citation

The Glooko Diabetes Mobile Monitoring and Management Advantage Study

TypeinterventionalSponsorGlookoRan2017 to 2020Enrolled197ConditionsDiabetes Mellitus, Type 2ArmsGlooko's mobile application
NCT03137966 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers

TypeinterventionalSponsorKarolinska University HospitalRan2022 to 2026Enrolled174ConditionsDiabetic Foot UlcerArmsDeferoxamine, Placebo
3 · Its place in the literature

Who cites it

1,814 citing papers in PubMed, 23 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Guideline
  8. Metformin for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2024 · on this map
    Pooled it
  9. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Pooled it
  15. Pooled it
  16. Blood pressure control for diabetic retinopathy.The Cochrane database of systematic reviews · 2023
    Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Guideline

1,754 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectiveTo determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes.

designRandomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg.

setting20 hospital based clinics in England, Scotland, and Northern Ireland. SUBJECTS: 1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years.

main outcome measuresPredefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography.

resultsMean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P<0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures.

conclusionTight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.

Indexed as

Adrenergic beta-AntagonistsAlbuminuriaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtenololBlood GlucoseCaptoprilCerebrovascular DisordersDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic RetinopathyFemaleFollow-Up StudiesHumansHypertensionHypoglycemiaAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtenololBlood GlucoseCaptopril

Identifiers

PMID9732337
PMCPMC28659

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.